• Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis 

      Albert, MH; Slatter, MA; Gennery, ar; Güngör, T; Bakunina, K; Markovitch, B; Hazelaar, S; Sirait, T; Courteille, V; Aiuti, A; Aleinikova, OV; Balashov, D; Bernardo, ME; Bodova, I; Bruno, B; Cavazzana, M; Chiesa, R; Fischer, A; Hauck, F; Ifversen, M; Kałwak, K; Klein, C; Kulagin, A; Kupesiz, A; Kuskonmaz, Baris; Lindemans, CA; Locatelli, F; Lum, SH; Maschan, A; Meisel, R; Moshous, D; Porta, F; Sauer, MG; Sedlacek, P; Schulz, A; Suarez, F; Vallée, TC; Winiarski, JH; Zecca, M; Neven, B; Veys, P; Lankester, AC (2022-03)
      Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for patients affected by Wiskott-Aldrich syndrome (WAS). Reported HSCT outcomes have improved over time with respect to overall ...